基于微阵列的cfDNA产前筛查胎儿三体的系统评价与meta分析
该系统评价与meta分析评估了使用微阵列定量母体血浆cfDNA的无创产前检测(NIPT)对胎儿21、18、13三体的检测准确性。共纳入5项研究、3074例样本,21、18、13三体的灵敏度分别为99.5%、97.7%、100%,特异度均接近100%,但所有研究存在高偏倚风险。
要点
- 微阵列cfDNA对21三体灵敏度99.5%、特异度100%
- 对18和13三体灵敏度分别为97.7%和100%,特异度均99.97%
- 合并检测失败率1.1%,微阵列与测序法准确性相当
核心结论
- 基于微阵列的cfDNA NIPT对胎儿21、18、13三体具有高灵敏度和特异度,但证据基础较小且偏倚风险高。
研究设计与样本
- 系统评价与meta分析,检索MEDLINE、Pre-MEDLINE、EMBASE、Web of Science和Cochrane Library至2018年7月9日。
- 纳入5项研究,共分析3074例样本,包括187例21三体、43例18三体和19例13三体。
主要发现
- 21三体灵敏度99.5%(95%CI 96.3%-99.9%),特异度100%(95%CI 99.87%-100%)。
- 18三体灵敏度97.7%(95%CI 87.9%-99.6%),特异度99.97%(95%CI 99.81%-99.99%)。
- 13三体灵敏度100%(95%CI 83.2%-100%),特异度99.97%(95%CI 99.81%-99.99%)。
- 合并检测失败率为1.1%。
- 微阵列与测序法cfDNA的直接比较显示检测准确性相当。
临床怎么用
- 微阵列cfDNA检测可作为胎儿21、18、13三体的产前筛查选项,但需注意证据偏倚风险高。
局限性
- 所有纳入研究偏倚风险高,主要源于分析排除和申办方角色。
- 证据基础较小,仅5项研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the test accuracy of non-invasive prenatal testing (NIPT) for fetal trisomy 21, 18, and 13 using cell-free (cf) DNA analysis in maternal plasma with microarray quantitation. METHOD: Systematic review and meta-analysis. Searches in MEDLINE, Pre-MEDLINE, EMBASE, Web of Science, and the Cochrane Library to 09.07.2018. RESULTS: Five studies analyzing 3074 samples, including 187 trisomy 21, 43 trisomy 18, and 19 trisomy 13 cases, were identified. Risk of bias was high in all studies, introduced particularly by exclusions from analysis and by the role of the sponsor. Sensitivity of microarray-based cfDNA testing was 99.5% (95%CI 96.3%-99.9%) for trisomy 21, 97.7% (95%CI 87.9%-99.6%) for trisomy 18, and 100% (95%CI 83.2%-100%) for trisomy 13. Specificity was 100% (95% CI 99.87%-100%) for trisomy 21, 99.97% (95%CI 99.81%-99.99%) for trisomy 18, and 99.97% (95%CI 99.81%-99.99%) for trisomy 13. Pooled test failure rate was 1.1%. A direct comparison of microarray- and sequencing-based cfDNA found equivalent test accuracy. CONCLUSION: Included studies suggest that NIPT using microarray-based cfDNA testing has high sensitivity and specificity for detecting fetal trisomy 21, 18, and 13. However, the evidence base is small and at high risk of bias.
引用
- Geppert J, Stinton C, Johnson S, et al. Antenatal screening for fetal trisomies using microarray-based cell-free DNA testing: A systematic review and meta-analysis. Prenat Diagn. 2019. PMID: 31834626. doi:10.1002/pd.5621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。